MRNY trades on NYSE Arca and carries a reported expense ratio of approximately 1.00%. The fund has experienced notable volatility, reflecting both the underlying movement in Moderna stock and the mechanics of its option-based income strategy. Over the trailing month, MRNY has changed hands in a range between roughly $34 and $48, while its 52-week range spans from $13.60 to $47.94.
This wide band underscores the fund's sensitivity to Moderna's share price, which can swing sharply on clinical, regulatory, and commercial news. Because the strategy writes call options, MRNY's upside is intentionally limited in exchange for the option premium that funds its frequent distributions. For income-focused investors, the fund's weekly payout cadence is a defining feature, though it comes with meaningful price volatility and the potential for net asset value erosion over time. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the sector.
MRNY is an actively managed exchange-traded fund issued by YieldMax and launched on October 23, 2023. Its primary objective is to generate current income, with a secondary objective of seeking exposure to the share price of Moderna (MRNA), subject to a cap on potential investment gains.
The fund implements a synthetic covered-call strategy, using both standardized exchange-traded and FLEX options, and is collateralized with cash and short-term U.S. Treasury securities. By selling call options against its Moderna exposure, MRNY collects premiums that are passed through to shareholders as distributions. This structure means the fund tends to capture less of Moderna's upside during strong rallies but can generate income in flat, choppy, or mildly declining markets.
Investors follow MRNY primarily for its income potential and its concentrated, derivative-based exposure to one large-cap biotechnology company, rather than for broad diversification.
Recent trading has reflected sharp swings in Moderna shares alongside a steady stream of distribution announcements. In late October, YieldMax announced weekly distributions for its Group 2 weekly-pay ETFs, and MRNY's recent weekly distributions have ranged from approximately $0.57 to $0.89 per share. The fund's distribution level fluctuates with option premiums, which in turn depend on Moderna's implied volatility and prevailing market conditions.
Price action has been choppy. After trading near the mid-$40s in mid-to-late October, MRNY pulled back sharply in late October before recovering into early November, illustrating how quickly the fund can reprice when its underlying moves. These swings are characteristic of a single-stock option-income product and highlight why the fund's total return cannot be evaluated on price alone; distributions represent a substantial component of shareholder economics.
Looking ahead, MRNY's performance will hinge on several intersecting factors. First is Moderna's underlying business: its respiratory vaccine franchise, clinical pipeline progress, and cost-management execution will drive the share price that anchors this fund's returns. Second is the options market itself, where implied volatility determines the premiums the fund can collect and, by extension, the size of its weekly distributions.
Investors should also monitor interest rates, since Treasury collateral income contributes to the fund's total return, and distribution sustainability, because unusually high yields can signal elevated risk or declining net asset value. Finally, the capped upside means MRNY will structurally underperform Moderna during prolonged rallies, a trade-off income investors should weigh carefully against the regular payouts the strategy is designed to provide. From what I see, this is important because the interplay between volatility and premiums will likely remain the dominant driver.
In my research process, I often turn to Tickeron’s Trending AI Robots page to review a curated selection of AI-driven trading bots. This resource draws from a platform offering hundreds of automated strategies across thousands of tickers, highlighting only the top-performing and most relevant ones. The bots cover a range of approaches, from short-term momentum to longer-horizon trend following, which can provide data-backed perspectives that complement fundamental analysis of funds like MRNY.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for MRNY moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In 15 of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNY as a result. In 46 of 51 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNY turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 21 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
MRNY broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNY advanced for three days, in 157 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 72 of 82 cases where MRNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.